Technical Analysis for ARRY - Array BioPharma Inc.
|Grade||Last Price||% Change||Price Change|
ARRY closed down 0.92 percent on Friday, June 22, 2018, on 1.65 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical ARRY trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 22||Slingshot Bullish||Bullish Swing Setup||0.00%|
|Jun 22||Overbought Stochastic||Strength||0.00%|
|Jun 21||New 52 Week High||Strength||-0.92%|
|Jun 21||Upper Bollinger Band Walk||Strength||-0.92%|
|Jun 21||Multiple of Ten Bearish||Other||-0.92%|
|Jun 21||Overbought Stochastic||Strength||-0.92%|
|Jun 21||Upper Bollinger Band Touch||Strength||-0.92%|
|Jun 20||New 52 Week Closing High||Bullish||-3.10%|
|Jun 20||New Uptrend||Bullish||-3.10%|
|Jun 20||New 52 Week High||Strength||-3.10%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ARRY news...
|52 Week High||20.21|
|52 Week Low||7.15|
|200-Day Moving Average||14.0677|
|50-Day Moving Average||15.8568|
|20-Day Moving Average||17.698|
|10-Day Moving Average||18.528|
|Average True Range||0.8952|
|Chandelier Exit (Long, 3 ATRs )||17.5244|
|Chandelier Exit (Short, 3 ATRs )||18.0656|
|Upper Bollinger Band||20.0335|
|Lower Bollinger Band||15.3625|
|Percent B (%b)||0.86|
|MACD Signal Line||0.8361|
|Market Cap||3.32 Billion|
|Num Shares||171 Million|
|Price-to-Earnings (P/E) Ratio||-26.90|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||20.90|
|Resistance 3 (R3)||20.90||20.39||20.65|
|Resistance 2 (R2)||20.39||20.00||20.39||20.56|
|Resistance 1 (R1)||19.88||19.76||19.63||19.88||20.47|
|Support 1 (S1)||18.86||18.98||18.61||18.86||18.27|
|Support 2 (S2)||18.35||18.74||18.35||18.18|
|Support 3 (S3)||17.84||18.35||18.10|
|Support 4 (S4)||17.84|